Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620969 | 0.90 | EDNRB (0.30) | — | |
| SCHEMBL3616132 | 0.90 | KMT2A (0.34) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL3621834 | 0.86 | KMT2A (0.33) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL3611247 | 0.76 | PTGS2 (0.40) | SMN1; SMN2KMT2ALMNACYP2C9TSHR | |
| SCHEMBL10019353 | 0.76 | MEN1 (0.36) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL3616326 | 0.76 | MEN1 (0.36) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL3607384 | 0.76 | KMT2A (0.33) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL3621884 | 0.75 | LMNA (0.34) | SMN1; SMN2KMT2ALMNACYP2C9TSHR | |
| SCHEMBL3576141 | 0.68 | CYP2C9 (0.38) | SMN1; SMN2RAB9AMAPTKMT2ALMNA | |
| SCHEMBL896318 | 0.63 | CNR2 (0.37) | NPC1RAB9AMAPTKMT2ACRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029668-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-02-04 | — | — | US | claimed |
| EP-2049521-A2 | NOVEL PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-04-22 | — | — | EP | claimed |
| WO-2008009405-A2 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-20100029668-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2049521-A2 | NOVEL PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008009405-A2 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029668-A1 | NOVEL PYRIDAZINE DERIVATIVES | C3AR1, C5, C1S | SMN1; SMN2 4685/4885NPC1 2554/4885RAB9A 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.